aTyr Pharma Company Profile (NASDAQ:LIFE)

About aTyr Pharma (NASDAQ:LIFE)

aTyr Pharma logoaTyr Pharma, Inc. is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B. The Company is developing Resolaris, an intravenous protein therapeutic for the treatment of rare myopathies with an immune component (RMICs). The Company is investigating Resolaris in patients with LGMD2B. The Company is conducting approximately three open label trials in patients with early onset FSHD, in adult patients with FSHD or LGMD2B and a long-term extension study in adult patients with FSHD. The Company has not generated any revenues.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Life Sciences Tools & Services
  • Symbol: NASDAQ:LIFE
  • CUSIP: 53217V10
  • Web:
  • Market Cap: $92.38 million
  • Outstanding Shares: 23,839,000
Average Prices:
  • 50 Day Moving Avg: $3.43
  • 200 Day Moving Avg: $3.43
  • 52 Week Range: $2.10 - $4.45
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.13
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $1.68 per share
  • Price / Book: 2.31
  • EBIDTA: ($50,670,000.00)
  • Return on Equity: -91.30%
  • Return on Assets: -70.74%
  • Debt-to-Equity Ratio: 0.29%
  • Current Ratio: 6.13%
  • Quick Ratio: 6.13%
  • Average Volume: 105,243 shs.
  • Beta: 3.76
  • Short Ratio: 13.67

Frequently Asked Questions for aTyr Pharma (NASDAQ:LIFE)

What is aTyr Pharma's stock symbol?

aTyr Pharma trades on the NASDAQ under the ticker symbol "LIFE."

How were aTyr Pharma's earnings last quarter?

aTyr Pharma, Inc. (NASDAQ:LIFE) posted its earnings results on Monday, August, 14th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.57) by $0.06. View aTyr Pharma's Earnings History.

When will aTyr Pharma make its next earnings announcement?

aTyr Pharma is scheduled to release their next quarterly earnings announcement on Monday, November, 13th 2017. View Earnings Estimates for aTyr Pharma.

Where is aTyr Pharma's stock going? Where will aTyr Pharma's stock price be in 2017?

4 equities research analysts have issued 1 year price targets for aTyr Pharma's stock. Their forecasts range from $2.85 to $7.00. On average, they expect aTyr Pharma's stock price to reach $4.46 in the next twelve months. View Analyst Ratings for aTyr Pharma.

Who are some of aTyr Pharma's key competitors?

Who are aTyr Pharma's key executives?

aTyr Pharma's management team includes the folowing people:

  • John K. Clarke, Independent Chairman of the Board
  • John D. Mendlein Ph.D., Chief Executive Officer, Director
  • John T. Blake, Senior Vice President - Finance
  • David John King Ph.D., Senior Vice President - Research
  • Grove Matsuoka, Senior Vice President, Product Programs and Planning
  • Ashraf Amanullah Ph.D., Vice President, Biologics Development and Manufacturing
  • Sanuj K. Ravindran M.D., Chief Business Officer
  • Sanjay S. Shukla M.D., Chief Medical Officer
  • Timothy P. Coughlin CPA, Director
  • Jeffrey S. Hatfield, Director

When did aTyr Pharma IPO?

(LIFE) raised $76 million in an initial public offering (IPO) on Thursday, May 7th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Citigroup served as the underwriters for the IPO and BMO Capital Markets and William Blair were co-managers.

Who owns aTyr Pharma stock?

aTyr Pharma's stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (14.94%), EcoR1 Capital LLC (9.63%), Vanguard Group Inc. (1.83%), Dimensional Fund Advisors LP (0.24%) and Northern Trust Corp (0.15%). Company insiders that own aTyr Pharma stock include Ashraf Amanullah, Grove Matsuoka, John Mendlein and Paul Schimmel. View Institutional Ownership Trends for aTyr Pharma.

Who bought aTyr Pharma stock? Who is buying aTyr Pharma stock?

aTyr Pharma's stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc.. Company insiders that have bought aTyr Pharma stock in the last two years include Ashraf Amanullah, Grove Matsuoka, John Mendlein and Paul Schimmel. View Insider Buying and Selling for aTyr Pharma.

How do I buy aTyr Pharma stock?

Shares of aTyr Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is aTyr Pharma's stock price today?

One share of aTyr Pharma stock can currently be purchased for approximately $3.88.

MarketBeat Community Rating for aTyr Pharma (NASDAQ LIFE)
Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  207 (Vote Outperform)
Underperform Votes:  249 (Vote Underperform)
Total Votes:  456
MarketBeat's community ratings are surveys of what our community members think about aTyr Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for aTyr Pharma (NASDAQ:LIFE) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.25)
Consensus Price Target: $4.46 (15.16% upside)

Analysts' Ratings History for aTyr Pharma (NASDAQ:LIFE)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/7/2017Piper Jaffray CompaniesInitiated CoverageOverweight -> Overweight$7.00HighView Rating Details
8/15/2017BMO Capital MarketsSet Price TargetHold$4.00HighView Rating Details
3/20/2017Citigroup Inc.Boost Price TargetNeutral$3.00 -> $4.00MediumView Rating Details
3/18/2017J P Morgan Chase & CoReiterated RatingHoldMediumView Rating Details
3/31/2016William BlairDowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 9/22/2015 forward)


Earnings History for aTyr Pharma (NASDAQ:LIFE)
Earnings by Quarter for aTyr Pharma (NASDAQ:LIFE)
Earnings History by Quarter for aTyr Pharma (NASDAQ LIFE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/13/2017N/AView Earnings Details
8/14/2017Q2 2017($0.57)($0.51)ViewN/AView Earnings Details
5/11/2017Q1 2017($0.50)($0.56)ViewN/AView Earnings Details
11/14/2016Q3 2016($0.67)($0.58)ViewN/AView Earnings Details
8/10/2016Q216($0.71)($0.65)ViewN/AView Earnings Details
5/11/2016Q1($0.70)($0.68)ViewN/AView Earnings Details
3/30/2016Q4($0.52)($0.70)ViewN/AView Earnings Details
11/10/2015Q3($0.48)($0.48)ViewN/AView Earnings Details
8/12/2015Q215($0.53)($0.74)ViewN/AView Earnings Details
6/18/2015Q115($0.41)($0.38)ViewN/AView Earnings Details
11/5/2013Q313$0.97$1.02$926.10 million$936.00 millionViewN/AView Earnings Details
7/31/2013Q2 2013$0.96$0.72$952.06 million$944.00 millionViewN/AView Earnings Details
5/2/2013Q1 2013$1.04$1.07$958.56 million$963.00 millionViewN/AView Earnings Details
2/4/2013Q4 2012$1.11$1.11$988.85 million$998.90 millionViewN/AView Earnings Details
11/1/2012Q312$0.89$0.92$907.91 million$911.00 millionViewN/AView Earnings Details
7/31/2012$0.97$0.96ViewN/AView Earnings Details
2/7/2012$1.04$1.06ViewN/AView Earnings Details
10/25/2011$0.88$0.94ViewN/AView Earnings Details
7/28/2011$0.95$0.89ViewN/AView Earnings Details
4/26/2011$0.85$0.85ViewN/AView Earnings Details
2/3/2011$0.87$0.90ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for aTyr Pharma (NASDAQ:LIFE)
2017 EPS Consensus Estimate: ($2.08)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.49)($0.49)($0.49)
Q2 20171($0.50)($0.50)($0.50)
Q3 20171($0.53)($0.53)($0.53)
Q4 20171($0.56)($0.56)($0.56)
(Data provided by Zacks Investment Research)


Dividend History for aTyr Pharma (NASDAQ:LIFE)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for aTyr Pharma (NASDAQ:LIFE)
Insider Ownership Percentage: 33.30%
Institutional Ownership Percentage: 46.66%
Insider Trades by Quarter for aTyr Pharma (NASDAQ:LIFE)
Institutional Ownership by Quarter for aTyr Pharma (NASDAQ:LIFE)
Insider Trades by Quarter for aTyr Pharma (NASDAQ:LIFE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/31/2017John MendleinCEOBuy37,736$2.65$100,000.40View SEC Filing  
8/31/2017Paul SchimmelDirectorBuy94,336$2.65$249,990.40View SEC Filing  
4/24/2017John MendleinCEOBuy124$3.00$372.00View SEC Filing  
4/20/2017John MendleinCEOBuy2,552$3.00$7,656.00View SEC Filing  
12/21/2016Paul SchimmelDirectorBuy25,000$2.28$57,000.00View SEC Filing  
12/20/2016Ashraf AmanullahVPBuy11,000$2.25$24,750.00View SEC Filing  
12/19/2016John MendleinCEOBuy69,000$2.20$151,800.00View SEC Filing  
12/16/2016Paul SchimmelDirectorBuy50,000$2.48$124,000.00View SEC Filing  
5/11/2016Grove MatsuokaInsiderBuy12,412$3.04$37,732.48View SEC Filing  
4/14/2016Paul SchimmelDirectorBuy66,219$4.18$276,795.42View SEC Filing  
4/13/2016Paul SchimmelDirectorBuy9,835$3.85$37,864.75View SEC Filing  
4/12/2016Paul SchimmelDirectorBuy9,127$3.71$33,861.17View SEC Filing  
4/11/2016Paul SchimmelDirectorBuy32,659$3.57$116,592.63View SEC Filing  
4/8/2016Paul SchimmelDirectorBuy85,000$3.22$273,700.00View SEC Filing  
4/7/2016Paul SchimmelDirectorBuy40,000$3.19$127,600.00View SEC Filing  
4/6/2016Paul SchimmelDirectorBuy25,000$3.20$80,000.00View SEC Filing  
4/5/2016John MendleinCEOBuy2,500$3.55$8,875.00View SEC Filing  
4/5/2016Paul SchimmelDirectorBuy25,000$3.52$88,000.00View SEC Filing  
5/12/2015James E FlynnInsiderBuy50,000$14.00$700,000.00View SEC Filing  
5/12/2015Sofinnova Venture Partners Ix,Major ShareholderBuy320,000$14.00$4,480,000.00View SEC Filing  
5/29/2013David C UprichardDirectorSell2,010$74.04$148,820.40View SEC Filing  
5/28/2013John A CottinghamInsiderSell60,000$74.03$4,441,800.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for aTyr Pharma (NASDAQ:LIFE)
Latest Headlines for aTyr Pharma (NASDAQ:LIFE)
DateHeadline logo Brokerages Expect aTyr Pharma, Inc. (LIFE) to Announce -$0.53 EPS - September 19 at 12:26 AM logoaTyr Pharma, Inc. (LIFE) Upgraded by Zacks Investment Research to "Buy" - September 17 at 1:32 PM logoaTyr Pharma, Inc. (LIFE) Cut to "Hold" at Zacks Investment Research - September 16 at 7:44 PM logoaTyr Pharma, Inc. (LIFE) Upgraded to "Sell" by ValuEngine - September 15 at 9:50 PM logoPiper Jaffray Companies Begins Coverage on aTyr Pharma, Inc. (LIFE) - September 10 at 10:14 AM logoZacks Investment Research Lowers aTyr Pharma, Inc. (LIFE) to Hold - September 8 at 12:36 AM logoaTyr Pharma, Inc. (LIFE) Receives Consensus Rating of "Hold" from Analysts - September 7 at 10:26 AM logoaTyr Pharma to Present at Two Upcoming Investor Conferences in September - September 6 at 2:03 AM logoInsider Buying: aTyr Pharma, Inc. (LIFE) CEO Buys 37,736 Shares of Stock - September 5 at 10:27 PM logoInsider Buying: aTyr Pharma, Inc. (LIFE) Director Buys 94,336 Shares of Stock - September 5 at 10:26 PM logoaTyr Pharma (LIFE) Reports $45M Private Placement - August 29 at 1:07 AM logoaTyr Pharma Announces $45 Million Equity Financing - August 28 at 8:05 PM logo[$$] Publicly Traded Rare Disease Drug-Maker aTyr Pharma Gets $46 Million Lift - August 28 at 8:05 PM logoaTyr Pharma, Inc. (LIFE) Upgraded to Buy by Zacks Investment Research - August 22 at 11:58 AM logoZacks Investment Research Downgrades aTyr Pharma, Inc. (LIFE) to Hold - August 19 at 10:30 AM logoWilliam Blair Analysts Lift Earnings Estimates for aTyr Pharma, Inc. (LIFE) - August 17 at 8:22 AM logoaTyr Pharma, Inc. (LIFE) Releases Earnings Results, Beats Estimates By $0.06 EPS - August 15 at 2:38 PM logoaTyr Pharma, Inc. (LIFE) Given "Hold" Rating at BMO Capital Markets - August 15 at 1:06 PM logoaTyr Pharma Announces Second Quarter 2017 Operating Results and Provides an Update on Innovative Immunology Pipeline - August 15 at 1:02 AM logoAtyr Pharma reports 2Q loss - August 15 at 1:02 AM logoaTyr Pharma, Inc. (NASDAQ:LIFE) Expected to Announce Earnings of -$0.57 Per Share - August 13 at 2:24 AM logoaTyr Pharma Announces Date of Earnings Release For Second Quarter 2017 Financial Results - August 11 at 6:08 AM logoaTyr Pharma, Inc. (NASDAQ:LIFE) to Release Quarterly Earnings on Tuesday - August 1 at 7:17 AM logoaTyr Pharma, Inc. (LIFE) Rating Increased to Hold at ValuEngine - July 8 at 10:10 PM logo-$0.57 EPS Expected for aTyr Pharma, Inc. (LIFE) This Quarter - June 29 at 4:29 PM logo-$0.57 Earnings Per Share Expected for aTyr Pharma Inc (LIFE) This Quarter - June 5 at 2:14 PM logoaTyr Pharma to Present at Jefferies 2017 Global Healthcare Conference - May 31 at 6:43 PM logoaTyr Pharma Inc (LIFE) Receives "Hold" Rating from BMO Capital Markets - May 24 at 11:32 AM logoaTyr Pharma Announces Presentations on Interstitial Lung Disease and the iMod.Fc Program at the American Thoracic Society 2017 International Conference and Will Host an Educational Webinar - May 15 at 10:38 AM logoaTyr Pharma Inc (LIFE) Posts Earnings Results, Misses Expectations By $0.06 EPS - May 12 at 11:48 AM
News IconUPDATE 1-Contract medical research firm INC to buy inVentiv in $4.6 bln deal - May 11 at 11:47 PM logoContract medical research firm INC to buy inVentiv in $4.6 billion deal - May 11 at 11:47 PM logoaTyr Pharma Announces First Quarter 2017 Operating Results - May 11 at 6:46 PM logoAtyr Pharma reports 1Q loss - May 11 at 6:46 PM logo-$0.55 Earnings Per Share Expected for aTyr Pharma Inc (LIFE) This Quarter - May 10 at 12:10 AM logoaTyr Pharma Inc (LIFE) Set to Announce Earnings on Tuesday - May 7 at 7:18 AM logoaTyr Pharma (LIFE) Earns Daily News Impact Rating of -0.10 - April 28 at 2:44 PM logoaTyr Pharma (LIFE) Reports Top-Line Results from Resolaris Phase 1b/2 Trial - April 24 at 7:23 PM logoaTyr Pharma (LIFE) Earns News Impact Score of -0.12 - April 23 at 3:13 PM logoaTyr Pharma (LIFE) Given Coverage Optimism Rating of -0.06 - April 20 at 3:47 PM logoZacks: Analysts Expect aTyr Pharma Inc (LIFE) to Post -$0.55 Earnings Per Share - April 19 at 7:56 AM logoaTyr Pharma (LIFE) Getting Somewhat Critical Media Coverage, Report Finds - April 14 at 1:08 PM logoaTyr Pharma Announces Appointment of Timothy P. Coughlin to its Board of Directors - April 10 at 5:55 PM logoShort Interest in aTyr Pharma Inc (LIFE) Drops By 9.3% - April 10 at 3:46 PM logoaTyr Pharma Announces Appointment of Jeffery S. Hatfield to its Board of Directors - Yahoo Finance - April 4 at 8:02 AM logoATYR PHARMA INC Files SEC form 8-K, Change in Directors or Principal Officers - April 4 at 8:02 AM logoaTyr Pharma to Present at Needham and Company 16th Annual Healthcare Conference - March 29 at 10:10 AM logoaTyr Pharma Inc (LIFE) Price Target Raised to $4.00 at Citigroup Inc - March 24 at 11:31 AM logoATYR PHARMA INC Financials - March 22 at 6:26 PM logoaTyr Pharma Inc (LIFE) Given New $4.00 Price Target at Citigroup Inc - March 20 at 12:32 PM



aTyr Pharma (LIFE) Chart for Friday, September, 22, 2017

This page was last updated on 9/22/2017 by Staff